Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits

Pediatrics International

Volumn 47, Issue 3, 2005, Pages 242-247

  Gong, Fangqi ^a   Tang, Hongfeng ^a   Lin, Yumin ^a   Gu, Weizhong ^a   Wang, Wei ^a   Kang, Manli ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bleomycin; Gene; Pulmonary hypertension; VEGF

Indexed keywords

BLEOMYCIN; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EOSIN; HEMATOXYLIN; LIPOSOME; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA DRUG COMPLEX; ENDOTHELIUM CELL; GENE TRANSFER; IMMATURITY; IN SITU HYBRIDIZATION; LUNG ARTERY PRESSURE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT; STATISTICAL ANALYSIS; TRANSGENE;

ANIMALS; BLEOMYCIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; HYPERTENSION, PULMONARY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY ARTERY; RABBITS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20444465266     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200x.2005.02060.x     Document Type: Article

References (24)

1. Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236-50.
2. Kunieda T, Nakanishi N, Satoh T, Kyotani S, Okano Y, Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern. Med. 1999; 38: 543-6.
3. Schmiedt MI, Shettigar UR, Siddique M, Barbier G, Bialow M, Carranza S. Unpredictable response to vasodilator therapy in primary pulmonary hypertension. Int. J. Clin. Pharmacol. Ther. 1998; 36: 435-40.
4. Castro PF, Bourge RC, McGiffin DC et al. Intrapulmonary shunting in primary pulmonary hypertension: An observation in two patients treated with epoprostenol sodium. Chest 1998; 114: 334-6.
5. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: A review of potential applications. J. Mol. Med. 1999; 77: 364-76.
6. Journois D, Pouard P, Mauriat P, Malhere J, Vouhe P, Safran D. Inhaled nitro oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J. Thorac. Cardiovasc. Surg. 1994; 107: 1129-35.
7. Channick RN, Newhart JW, Johnson FW et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 1996; 109: 1545-9.
8. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346: 51-2.
9. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms. In: Rubin LJ, Rich S (eds). Primary Pulmonary Hypertension. Marcel Dekker, New York, NY, 1997; 83-133.
10. Gong FQ, Lin YM, Tang HF, Gu WZ, Wang W, Kang ML. VEGFmRNA and eNOSmRNA expression in immature rabbits with bleomycin-induced pulmonary hypertension. J. Zhejiang Univ. Sci. 2004; 5: 995-1000.
11. Partovian C, Adnot S, Raffestin B et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. J. Respir. Cell Mol. Biol. 2000; 23: 762-71.
12. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104: 2242-8.
13. Michel RP, Hakim TS, Freeman CR. Distribution of pulmonary vascular resistance in experimental fibrosis. J. Appl. Physiol. 1988; 65: 1180-90.
14. Bishop JE, Guerreiro D, Laurent GJ. Changes in the composition and metabolism of arterial collagens during the development of pulmonary hypertension in rabbits. Am. Rev. Respir. Dis. 1990; 141: 450-5.
15. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir. Cell Mol. Biol. 2003; 29: 375-80.
16. Champion HC, Bivalacqua TJ, D'Souza FM et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ. Res. 1999; 84: 1422-32.
17. Fehrenbach H, Haase M, Kasper M, Koslowski R, Schuh D, Muller M. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis. Virchows Arch. 1999; 435: 20-31.
18. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem. Biophys. Res. Commun. 1998; 252: 743-6.
19. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998; 274: H1054-8.
20. Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 1997; 99: 2625-34.
21. Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, Stewart DJ. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ. Res. 1998; 82: 1007-15.
22. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998; 273: 30336-43.
23. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998; 273: 13 313-16.
24. Campbell AI, Zhao Y, Sandhu R, Steward DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104: 2242-8.